Literature DB >> 27856346

Peptidomimetic therapeutics: scientific approaches and opportunities.

Nir Qvit1, Samuel J S Rubin2, Travis J Urban3, Daria Mochly-Rosen4, Eric R Gross5.   

Abstract

Natural endogenously occurring peptides exhibit desirable medicinal properties, but are often limited in application by rapid proteolysis and inadequate membrane permeability. However, editing naturally occurring peptide sequences to develop peptidomimetic analogs created a promising class of therapeutics that can augment or inhibit molecular interactions. Here, we discuss a variety of chemical modifications, including l to d isomerization, cyclization, and unnatural amino acid substitution, as well as design strategies, such as attachment to cell-penetrating peptides, which are used to develop peptidomimetics. We also provide examples of approved peptidomimetics and discuss several compounds in clinical trials.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27856346      PMCID: PMC5759319          DOI: 10.1016/j.drudis.2016.11.003

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  55 in total

Review 1.  Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure.

Authors:  H Gavras; H R Brunner
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

Review 2.  Intracellullar peptides as putative natural regulators of protein interactions.

Authors:  Emer S Ferro; Stephen Hyslop; Antonio C M Camargo
Journal:  J Neurochem       Date:  2004-11       Impact factor: 5.372

Review 3.  Is the oral route possible for peptide and protein drug delivery?

Authors:  Mariko Morishita; Nicholas A Peppas
Journal:  Drug Discov Today       Date:  2006-09-07       Impact factor: 7.851

4.  Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

Authors:  Dennis Kim; Leigh MacConell; Dongliang Zhuang; Prajakti A Kothare; Michael Trautmann; Mark Fineman; Kristin Taylor
Journal:  Diabetes Care       Date:  2007-03-12       Impact factor: 19.112

Review 5.  Contemporary strategies for peptide macrocyclization.

Authors:  Christopher J White; Andrei K Yudin
Journal:  Nat Chem       Date:  2011-06-23       Impact factor: 24.427

6.  Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.

Authors:  Mark R Gilbert; John Kuhn; Kathleen R Lamborn; Frank Lieberman; Patrick Y Wen; Minesh Mehta; Timothy Cloughesy; Andrew B Lassman; Lisa M Deangelis; Susan Chang; Michael Prados
Journal:  J Neurooncol       Date:  2011-07-08       Impact factor: 4.130

7.  Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions.

Authors:  Landon R Whitby; Yoshio Ando; Vincent Setola; Peter K Vogt; Bryan L Roth; Dale L Boger
Journal:  J Am Chem Soc       Date:  2011-06-15       Impact factor: 15.419

Review 8.  Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury.

Authors:  Hazel H Szeto
Journal:  Antioxid Redox Signal       Date:  2008-03       Impact factor: 8.401

9.  Therapies for diabetes: pramlintide and exenatide.

Authors:  Melissa C Jones
Journal:  Am Fam Physician       Date:  2007-06-15       Impact factor: 3.292

10.  Forcefield_NCAA: ab initio charge parameters to aid in the discovery and design of therapeutic proteins and peptides with unnatural amino acids and their application to complement inhibitors of the compstatin family.

Authors:  George A Khoury; James Smadbeck; Phanourios Tamamis; Andrew C Vandris; Chris A Kieslich; Christodoulos A Floudas
Journal:  ACS Synth Biol       Date:  2014-01-14       Impact factor: 5.110

View more
  44 in total

1.  Lipophilicity prediction of peptides and peptide derivatives by consensus machine learning.

Authors:  Jens-Alexander Fuchs; Francesca Grisoni; Michael Kossenjans; Jan A Hiss; Gisbert Schneider
Journal:  Medchemcomm       Date:  2018-08-22       Impact factor: 3.597

2.  Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration.

Authors:  Haiming Jiang; Rong Deng; Xiuyan Yang; Jialin Shang; Shaoyong Lu; Yanlong Zhao; Kun Song; Xinyi Liu; Qiufen Zhang; Yu Chen; Y Eugene Chinn; Geng Wu; Jian Li; Guoqiang Chen; Jianxiu Yu; Jian Zhang
Journal:  Nat Chem Biol       Date:  2017-07-24       Impact factor: 15.040

Review 3.  Factors affecting the physical stability (aggregation) of peptide therapeutics.

Authors:  Karolina L Zapadka; Frederik J Becher; A L Gomes Dos Santos; Sophie E Jackson
Journal:  Interface Focus       Date:  2017-10-20       Impact factor: 3.906

4.  Short Proline-Rich Lipopeptide Potentiates Minocycline and Rifampin against Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa.

Authors:  Ronald Domalaon; Yaroslav Sanchak; Linet Cherono Koskei; Yinfeng Lyu; George G Zhanel; Gilbert Arthur; Frank Schweizer
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  Rapid and accurate structure-based therapeutic peptide design using GPU accelerated thermodynamic integration.

Authors:  Michael Garton; Carles Corbi-Verge; Yuan Hu; Satra Nim; Nadya Tarasova; Brad Sherborne; Philip M Kim
Journal:  Proteins       Date:  2019-01-04

6.  Novel Cyclic Biphalin Analogues by Ruthenium-Catalyzed Ring Closing Metathesis: in Vivo and in Vitro Biological Profile.

Authors:  Azzurra Stefanucci; Wei Lei; Stefano Pieretti; Marilisa Pia Dimmito; Grazia Luisi; Ettore Novellino; Michał Nowakowski; Wiktor Koźmiński; Sako Mirzaie; Gokhan Zengin; John M Streicher; Adriano Mollica
Journal:  ACS Med Chem Lett       Date:  2019-03-08       Impact factor: 4.345

7.  Next Generation Techniques for Determination of Protein-Protein Interactions: Beyond the Crystal Structure.

Authors:  Rachel Carter; Alessandra Luchini; Lance Liotta; Amanda Haymond
Journal:  Curr Pathobiol Rep       Date:  2019-07-01

8.  Tissue distribution and metabolic profiling of cyclosporine (CsA) in mouse and rat investigated by DESI and MALDI mass spectrometry imaging (MSI) of whole-body and single organ cryo-sections.

Authors:  Niels Bjerre Holm; Maria Deryabina; Carsten Boye Knudsen; Christian Janfelt
Journal:  Anal Bioanal Chem       Date:  2022-08-11       Impact factor: 4.478

Review 9.  Peptidomimetics Therapeutics for Retinal Disease.

Authors:  Dylan E Parsons; Soo Hyeon Lee; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Mark Smith; Vinit B Mahajan
Journal:  Biomolecules       Date:  2021-02-24

Review 10.  Heterocycles as a Peptidomimetic Scaffold: Solid-Phase Synthesis Strategies.

Authors:  Aizhan Abdildinova; Mark J Kurth; Young-Dae Gong
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.